Of the three major subtypes of breast cancer, the triple negative is the most lethal and unlike other breast cancers, it is resistant to most existing therapies. By studying the properties of clofazimine, a 70-year-old antibiotic, scientists demonstrate its effectiveness in stopping the progression of the disease in in vivo tests. These results highlight the need to re-examine with a fresh eye the drugs already on the market.